Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The Pandemic Picture Is Becoming Clearer

The last time Pranay Laharia and Amadi Nze chatted about the COVID-19 pandemic in the summer, it wasn’t clear how much longer the public health crisis would continue. While we’re still not sure the exact date we’ll be able to stop utilizing masks and file back into places like full stadiums for a basketball…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

The last time Pranay Laharia and Amadi Nze chatted about the COVID-19 pandemic in the summer, it wasn’t clear how much longer the public health crisis would continue.

While we’re still not sure the exact date we’ll be able to stop utilizing masks and file back into places like full stadiums for a basketball game, a packed movie theater for a midnight showing or a cramped dive bar for a beer, Laharia said the picture is clearing up.

“There’s been some good news and some not so good news over the last five months. The good news is we have some phenomenal success on the vaccine front,” said Laharia, Director and Equity Health Care Analyst at Barrow Hanley.

The bad news, of course, is the number of cases, which experts expect only to rise as people gather to celebrate the holidays and spend more time inside, where the coronavirus is more likely to spread.

There is, however, a light at the end of the tunnel, with Laharia expecting vaccines from companies like Pfizer and Moderna to turn the tide and possibly even lead to an eradication of the virus, though how long-lasting the protection provided by those vaccines will be is yet to be determined.

Those vaccines utilize messenger RNA to create a spike protein that teaches the body how to attack the virus. Even if it mutates, it won’t take long to tamp down potential flair-ups.

“It’s a real blessing we have the messenger RNA technology ready in time for this pandemic. This pandemic is very, very quick to respond to any changes and mutations,” Lahria said. “Once you have a mutation genetically sequenced, you can take that sequence and tweak your messenger RNA, which is really a synthetic molecule, to produce a different confirmation of the spike protein which would be associated with the mutated virus. You can do that within two to seven days.”

While distribution will pose a challenge, Lahria expects the cold shipment required for the Pfizer vaccine to be easier to handle than some media outlets have made it out to be, with the demand for the vaccine likely to make sure that few retail pharmacies need to store the vaccine for more than the five days it can last in most pharmacy refrigerators.

All that means while the pandemic is at its worst stage at time of writing, we can reasonably hope to be back to something resembling normal life at some point in 2021.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512